GSK 2132231A
111482
Phase 3 small_molecule terminated
Quick answer
GSK 2132231A for Melanoma is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Melanoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated